


Claims

1. A compound of Formula (A):



or a tautomer, or a pharmaceutically acceptable salt of any of the foregoing,

wherein

one of R^1 and R^2 is $-OH$ and the other is selected from the group consisting of $-CN$, halogen, $-C(O)R^a$, $-CH=NR^j$, $-S(O)R^b$, $-S(O)_2R^c$, $-NHC(O)R^d$, $-NHS(O)_2R^e$, $-C_1-C_6alkyl-R^f$, $-C_2-C_6alkenyl-R^g$, unsubstituted or substituted C_3-C_8 cycloalkyl, unsubstituted or substituted C_3-C_8 cycloalkenyl, and unsubstituted or substituted heterocycloalkyl;

R^a , R^b , R^c , and R^e are each independently H, C_1-C_6alkyl , $C_2-C_6alkenyl$, $C_2-C_6alkynyl$, $C_1-C_6haloalkyl$, unsubstituted or substituted heterocyclyl, unsubstituted or substituted heteroaryl, benzoyl, or styryl;

R^d is H, C_1-C_6alkyl , $C_2-C_6alkenyl$, $C_2-C_6alkynyl$, $C_1-C_6haloalkyl$, unsubstituted or substituted heterocyclyl, unsubstituted or substituted heteroaryl, or benzoyl;

R^f and R^g are each independently $-OH$, unsubstituted heteroaryl, $-NR^mR^n$, benzoyl, or styryl;

R^m and R^n are each independently H, C_1-C_6alkyl , $C_2-C_6alkenyl$, $C_2-C_6alkynyl$, or unsubstituted or substituted cycloalkyl;

R^j is unsubstituted or substituted heterocyclyl, unsubstituted or substituted heteroaryl, unsubstituted or substituted aryl, $-OR^k$, $-NHR^k$, $-NHC(O)R^k$, $-NHS(O)_2R^k$, or $-NHC(NH)NHR^{aa}$;

R^{aa} is unsubstituted or substituted C_1-C_6alkyl , unsubstituted or substituted C_3-C_8 cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted heterocycloalkyl, or unsubstituted or substituted heteroaryl;

R^k is C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_3 - C_8 cycloalkyl, or aryl, wherein the C_1 -

C_6 alkyl of R^k is unsubstituted or substituted with heterocyclyl or heteroaryl;

R^3 is H, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, or halogen, wherein the C_1 - C_6 alkyl and C_1 - C_6 alkoxy of R^3 are each independently unsubstituted or substituted with one or more halogen;

wherein when R^2 is Br, R^3 is H, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, Cl, F, or I;

G_1 and G_2 are each independently CH or N, wherein when G_1 is N, G_2 is CH, and when G_2 is N,

G_1 is CH;

 indicates that the ring is aromatic;

Y^1 is C or N;

Y^2 is CH, N, NH, S, or O;

Y^3 is C or N;

Y^4 is CH, N, NH, S, or O;


Y^5 is CR^7 , N, NH, S, or O;

wherein no more than one of Y^1 , Y^2 , Y^3 , Y^4 , and Y^5 is S or O and no more than four of

Y^1 , Y^2 , Y^3 , Y^4 , and Y^5 are N or NH;

R^7 is H or C_1 - C_6 alkyl;

n is 0, 1, 2, or 3;



R^4 is alkoxy or

 indicates that the ring is saturated, partially unsaturated, or fully unsaturated;



G_3 is $CH(X_1-R^{6a})$, $C(X_1-R^{6a})$, N, $N(X_1-R^{6a})$, S, or O;

G_4 is $CH(X_2-R^{6b})$, $C(X_2-R^{6b})$, N, $N(X_2-R^{6b})$, S, or O;

G_5 is $CH(X_3-R^{6c})$, $C(X_3-R^{6c})$, N, $N(X_3-R^{6c})$, S, or O;

G_6 is $CH(X_4-R^{6d})$, $C(X_4-R^{6d})$, N, $N(X_4-R^{6d})$, S, or O; and

G_7 is N, C, or CH;

X_1 , X_2 , X_3 , and X_4 are each independently absent, , or ;

m is 1-6;

R^{6a} , R^{6b} , R^{6c} , and R^{6d} are each independently hydrogen, C₁-C₆alkyl, C₁-C₆alkoxy, halo, -OH, -NR^pR^q, aryl, heterocyclyl, heteroaryl, -C₁-C₆alkyl-heterocyclyl, -OC(O)-heterocyclyl, -C(O)R^h, -S(O)₂NR^{w1}R^{w2}, -S(O)₂R^y, or -NR^{z1}S(O)₂R^{z2}, wherein the C₁-C₆alkyl and C₁-C₆alkoxy of R^{6a} , R^{6b} , R^{6c} , and R^{6d} are each independently unsubstituted or substituted with one or more groups selected from the group consisting of cycloalkyl and halogen; the aryl and heteroaryl of R^{6a} , R^{6b} , R^{6c} , and R^{6d} are each independently unsubstituted or substituted with one or more groups selected from the group consisting of C₁-C₆alkyl, C₁-C₆alkoxy, C₃-C₈cycloalkyl, -OH, and C₁-C₆alkyl-OH; and the heterocyclyl, -C₁-C₆alkyl-heterocyclyl, and -OC(O)-heterocyclyl of R^{6a} , R^{6b} , R^{6c} , and R^{6d} are each independently unsubstituted or substituted with one or more groups selected from the group consisting of C₁-C₆alkyl, C₁-C₆alkoxy, halo, -OH, C₁-C₆alkyl-OH, =O, and =S; each R^h is independently selected from the group consisting of H, C₁-C₆alkyl, C₁-C₆alkoxy, and C₃-C₈cycloalkyl, and -NR^rR^s;

each R^p is independently H or C₁-C₆alkyl;

each R^q is independently C₂-C₃alkyl, -C(O)R^t, -C(O)OR^u, -C(O)NR^v;

each R^r, R^s, R^{w1}, and R^{z1} is independently selected from H and C₁-C₆alkyl; and

each R^t, R^u, R^v, R^{w2}, R^y, and R^{z2} is independently selected from H, C₁-C₆alkyl, unsubstituted or substituted C₃-C₈cycloalkyl, and unsubstituted or substituted heterocyclyl;

or

G₅ is CH(X₃-R^{6c}) or C(X₃-R^{6c}), G₆ is CH(X₄-R^{6d}) or C(X₄-R^{6d}), and R^{6c} and R^{6d} are taken together with the carbon atoms to which they are attached to form a 6-membered aryl, a 6-membered heterocyclyl, or a 6-membered heteroaryl ring; wherein the 6-membered aryl, 6-membered heterocyclyl, and 6-membered heteroaryl rings are each independently unsubstituted or substituted.

2. The compound of claim 1, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing,

wherein

Y¹ is C or N;

Y² is CH, N, NH, S, or O;

Y³ is C or N;

Y⁴ is CH, N, NH, S, or O; and

Y^5 is CH, N, NH, S, or O;

wherein no more than one of Y^1 , Y^2 , Y^3 , Y^4 , and Y^5 is S or O and no more than three of Y^1 , Y^2 , Y^3 , Y^4 , and Y^5 are N or NH.


3. The compound of claim 1 or claim 2, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^1 is $-OH$ and R^2 is selected from the group consisting of $-CN$, halogen, $-C(O)R^a$, $-CH=NR^j$, $-S(O)R^b$, $-S(O)_2R^c$, $-NHC(O)R^d$, $-NHS(O)_2R^e$, $-C_1-C_6alkyl-R^f$, $-C_2-C_6alkenyl-R^g$, unsubstituted or substituted C_3-C_8 cycloalkyl, unsubstituted or substituted C_3-C_8 cycloalkenyl, and unsubstituted or substituted heterocycloalkyl.

4. The compound of any one of claims 1-3, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^1 is $-OH$ and R^2 is selected from the group consisting of $-CN$, halogen, $-C(O)R^a$, $-CH=NR^j$, $-C_2-C_6alkenyl-R^g$, and unsubstituted or substituted heterocycloalkyl.

5. The compound of any one of claims 1-4, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^1 is $-OH$ and R^2 is $-C(O)H$.

6. The compound of any one of claims 1-4, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^1 is $-OH$ and R^2 is $-CH=NR^j$, wherein R^j is unsubstituted or substituted heterocyclyl, unsubstituted or substituted heteroaryl, unsubstituted or substituted aryl, $-OR^k$, $-NHR^k$, $-NHC(O)R^k$, $-NHS(O)_2R^k$, or $-NHC(NH)NH_2$.

7. The compound of claim 1 or claim 2, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^1 is $-OH$ and R^2 is selected from the group




8. The compound of claim 1 or claim 2, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^2 is $-OH$ and R^1 is selected from the group consisting of $-CN$, halogen, $-C(O)R^a$, $-CH=NR^j$, $-S(O)R^b$, $-S(O)_2R^c$, $-NHC(O)R^d$, $-NHS(O)_2R^e$, $-C_1-C_6alkyl-R^f$, $-C_2-C_6alkenyl-R^g$, unsubstituted or substituted C_3-C_8 cycloalkyl, unsubstituted or substituted C_3-C_8 cycloalkenyl, and unsubstituted or substituted heterocycloalkyl.

9. The compound of any one of claims 1-2 and 8, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^2 is $-OH$ and R^1 is selected from the group consisting of $-CN$, halogen, $-C(O)R^a$, $-CH=NR^j$, $-C_2-C_6alkenyl-R^g$, and unsubstituted or substituted heterocycloalkyl.

10. The compound of any one of claims 1-2 and 8-9, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^2 is $-OH$ and R^1 is $-C(O)H$.

11. The compound of any one of claims 1-2 and 8-9, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^2 is $-OH$ and R^1 is $-CH=NR^j$, wherein R^j is unsubstituted or substituted heterocyclyl, unsubstituted or substituted heteroaryl, unsubstituted or substituted aryl, $-OR^k$, $-NHR^k$, $-NHC(O)R^k$, $-NHS(O)_2R^k$, or $-NHC(NH)NH_2$.


12. The compound of claim 1 or claim 2, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^2 is $-OH$ and R^1 is selected from the group




13. The compound of any one of claims 1-12, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^3 is selected from the group consisting of C_1 - C_6 alkyl, C_1 - C_6 alkoxy, and halogen.

14. The compound of any one of claims 1-12, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^3 is selected from the group consisting of $-CH_3$, $-OCH_3$, Cl and F.


15. The compound of any one of claims 1-14, or a tautomer thereof, or a pharmaceutically




16. The compound of any one of claims 1-15, or a tautomer thereof, or a pharmaceutically




17. The compound of any one of claims 1-15, or a tautomer thereof, or a pharmaceutically



18. The compound of any one of claims 1-15, or a tautomer thereof, or a pharmaceutically



19. The compound of any one of claims 1-15, or a tautomer thereof, or a pharmaceutically



20. The compound of any one of claims 1-19, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein n is 0.


21. The compound of any one of claims 1-19, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein n is 1.

22. The compound of any one of claims 1-19, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein n is 2.

23. The compound of any one of claims 1-19, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein n is 3.


24. The compound of any one of claims 1-23, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R⁴ is C₁-C₆ alkoxy.


25. The compound of any one of claims 1-23, or a tautomer thereof, or a pharmaceutically




acceptable salt of any of the foregoing, wherein R⁴ is


26. The compound of claim 25, or a tautomer thereof, or a pharmaceutically acceptable salt

of any of the foregoing, wherein G₃ is CH(X₁-R^{6a}) or C(X₁-R^{6a}); X₁ is absent, , or


; m is 1-6; R^{6a} is hydrogen, C₁-C₆alkyl, C₁-C₆haloalkyl, halo, C₆-C₁₂ aryl, 3- to 10-membered heterocyclyl, or 5- to 10-membered heteroaryl.

27. The compound of claim 25, or a tautomer thereof, or a pharmaceutically acceptable salt


of any of the foregoing, wherein G₃ is N or N(X₁-R^{6a}); X₁ is absent, , or

; m is 1-6; and R^{6a} is hydrogen, C₁-C₆alkyl, C₁-C₆haloalkyl, halo, C₆-C₁₂ aryl, 3- to 10-membered heterocyclyl, or 5- to 10-membered heteroaryl.


28. The compound of any one of claims 25-27, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein G_4 is $\text{CH}(\text{X}_2\text{-R}^{6b})$ or $\text{C}(\text{X}_2\text{-R}^{6b})$; X_2 is absent,




29. The compound of any one of claims 25-27, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein G_4 is N or $\text{N}(\text{X}_2\text{-R}^{6b})$; X_2 is absent,



30. The compound of any one of claims 25-29, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein G_5 is $\text{CH}(\text{X}_3\text{-R}^{6c})$ or $\text{C}(\text{X}_3\text{-R}^{6c})$; X_3 is absent,




31. The compound of any one of claims 25-29, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein G_5 is N or $\text{N}(\text{X}_3\text{-R}^{6c})$; X_3 is absent,




32. The compound of any one of claims 25-31, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein one of G_3 , G_4 , and G_5 is S or O .

33. The compound of any one of claims 25-31, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein G_6 is $\text{CH}(\text{X}_4\text{-R}^{6d})$ or $\text{C}(\text{X}_4\text{-R}^{6d})$; X_4 is absent,



34. The compound of any one of claims 25-31, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein G_6 is N or $N(X_4-R^{6d})$; X_4 is absent,



; m is 1-6; and R^{6d} is hydrogen, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, halo, C_6 - C_{12} aryl, 3- to 10-membered heterocyclyl, or 5- to 10-membered heteroaryl.

35. The compound of any one of claims 1-29 and 32, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein G_5 is $CH(X_3-R^{6c})$ or $C(X_3-R^{6c})$, G_6 is $CH(X_4-R^{6d})$ or $C(X_4-R^{6d})$, and R^{6c} and R^{6d} come together with the carbon atoms to which they are attached to form a 6-membered aryl, a 6-membered heterocyclyl, or a 6-membered heteroaryl ring; wherein the 6-membered aryl, 6-membered heterocyclyl, and 6-membered heteroaryl rings are each independently unsubstituted or substituted with one or more groups selected from the group consisting of C_1 - C_6 alkyl and $-C(O)O-C_1$ - C_6 alkyl.


36. The compound of any one of claims 25-35, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein G_7 is N.

37. The compound of any one of claims 25-35, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein G_7 is C or CH.

38. The compound of any one of claims 25-37, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein one or more of R^{6a} , R^{6b} , R^{6c} , and R^{6d} is selected from the group consisting of C_1 - C_6 alkyl, C_1 - C_6 alkoxy, halo, $-OH$, $-NR^pR^q$, aryl, heterocyclyl, heteroaryl, $-C_1$ - C_6 alkyl-heterocyclyl, $-OC(O)$ -heterocyclyl, $-C(O)R^h$, $-S(O)_2NR^{w1}R^{w2}$, $-S(O)_2R^y$, or $-NR^{z1}S(O)_2R^{z2}$.

39. The compound of any one of claims 25-37, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein one or more of R^{6a} , R^{6b} , R^{6c} , and R^{6d} is selected from the group consisting of C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, halo, C_6 - C_{12} aryl, 3- to 10-membered heterocyclyl, and 5- to 10-membered heteroaryl.

40. The compound of any one of claims 25-37, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein one of R^{6a} , R^{6b} , R^{6c} , and R^{6d} is selected from the group consisting of methyl, ethyl, methoxy, F, Cl, $-CF_3$, pyrrolidinyl, piperidinyl, morpholinyl, pyrazolyl, triazolyl, and tetrazolyl.
41. The compound of any one of claims 25-37, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^{6a} , R^{6b} , R^{6c} , and R^{6d} are each H.
42. The compound of any one of claims 1-41, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein G_1 is CH.
43. The compound of any one of claims 1-41, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein G_1 is N.
44. The compound of any one of claims 1-43, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein G_2 is CH.
45. The compound of any one of claims 1-42, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein G_2 is N.
46. A compound of Table 1A, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.
47. A compound of Formula (B):



or a tautomer, or a pharmaceutically acceptable salt of any of the foregoing,
wherein

L is selected from the group consisting of $-\text{C}\equiv\text{C}-$, $^*\text{-NHC(O)-}$, $^*\text{-C(O)NH-}$, -NHC(O)NH- , $^*\text{-NHS(O)}_2\text{-}$, $^*\text{-NHS(O)(=NH)-}$, $^*\text{-S(O)}_2\text{NH-}$, $^*\text{-S(O)NHNH-}$, $^*\text{-NHNHS(O)-}$, $^*\text{-C(O)NHNH-}$, $^*\text{-NHNHC(O)-}$, $^*\text{-NHC(O)O-}$, and $^*\text{-OC(O)NH-}$, wherein * represents the point of attachment to Y_7 ;

Y_1 and Y_2 are each independently CR^x or N;

R^x is hydrogen or halogen;

when L is $-\text{C}\equiv\text{C}-$, one of R^{1A} and R^{2A} is $-\text{OH}$ and the other is selected from the group consisting of $-\text{C(O)R}^{a1}$, $-\text{CH=NR}^{j1}$, $-\text{S(O)R}^{b1}$, $-\text{S(O)}_2\text{R}^{c1}$, $-\text{NHC(O)R}^{d1}$, $-\text{NHS(O)}_2\text{R}^{e1}$, $-\text{C}_1\text{-C}_6\text{alkyl-R}^{f1}$, $-\text{C}_2\text{-C}_6\text{alkenyl-R}^{g1}$, $\text{C}_3\text{-C}_8\text{ cycloalkyl}$, $\text{C}_3\text{-C}_8\text{ cycloalkenyl}$, and 5- or 6-membered heterocycloalkyl, wherein the $\text{C}_3\text{-C}_8\text{ cycloalkyl}$ and $\text{C}_3\text{-C}_8\text{ cycloalkenyl}$ are each independently unsubstituted or substituted with one or more $=\text{O}$, and the 5- or 6-membered heterocycloalkyl is unsubstituted or substituted with one or more substituents independently selected from the group consisting of $\text{C}_1\text{-C}_6\text{alkyl}$, $\text{C}_3\text{-C}_8\text{ cycloalkyl}$, $=\text{O}$, and $-\text{C(O)O-C}_1\text{-C}_6\text{alkyl}$;

when L is $^*\text{-NHC(O)-}$, $^*\text{-C(O)NH-}$, -NHC(O)NH- , $^*\text{-NHS(O)}_2\text{-}$, $^*\text{-S(O)}_2\text{NH-}$, $^*\text{-S(O)NHNH-}$, $^*\text{-C(O)NHNH-}$, or $^*\text{-NHC(O)O-}$, one of R^{1A} and R^{2A} is $-\text{OH}$ and the other is selected from

the group consisting of $-\text{C(O)H}$, $-\text{CH=NR}^{j1}$, and ;

R^{a1} is H, $\text{C}_1\text{-C}_6\text{alkyl}$, $\text{C}_2\text{-C}_6\text{alkenyl}$, $\text{C}_2\text{-C}_6\text{alkynyl}$, $\text{C}_1\text{-C}_6\text{haloalkyl}$, 3- to 6-membered heterocyclyl, or 5- to 10-membered heteroaryl, or benzoyl, wherein the 3- to 10-

membered heterocyclyl of R^{a1} is unsubstituted or substituted with one or more groups independently selected from the group consisting of C_1 - C_6 alkyl, C_3 - C_8 cycloalkyl, $=O$, and $-C(O)O$ - C_1 - C_6 alkyl, and the 5- to 10-membered heteroaryl of R^{a1} is unsubstituted or substituted with one or more groups independently selected from the group consisting of C_1 - C_6 alkyl, C_3 - C_8 cycloalkyl, and $-C(O)O$ - C_1 - C_6 alkyl;

R^{b1} , R^{c1} , R^{d1} , and R^{e1} are each independently H, C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 haloalkyl, 3- to 10-membered heterocyclyl, 5- to 10-membered heteroaryl, benzoyl, or styryl, wherein the 3- to 10-membered heterocyclyl and 5- to 10-membered heteroaryl of R^{b1} , R^{c1} , R^{d1} , and R^{e1} are each independently selected from the group consisting of C_1 - C_6 alkyl, C_3 - C_8 cycloalkyl, and $-C(O)O$ - C_1 - C_6 alkyl;

R^{f1} and R^{g1} are each independently $-OH$, unsubstituted 5- to 6-membered heteroaryl, $-NR^{m1}R^{n1}$, benzoyl, or styryl;

R^{m1} is C_3 - C_8 cycloalkyl, unsubstituted or substituted with one or more groups selected from C_1 - C_6 alkyl and halo;

R^{n1} is H, C_1 - C_6 alkyl, C_2 - C_6 alkenyl, or C_2 - C_6 alkynyl;

R^{j1} is C_1 - C_6 alkyl, 5- to 6-membered heterocyclyl, 5- to 6-membered heteroaryl, 6- to 12-membered aryl, $-OR^{k1}$, $-NHR^{k1}$, $-N(C_1-C_6alkyl)R^{k1}$, $-NHC(O)R^{k1}$, $-NHS(O)_2R^{k1}$, or $-NHC(NH)NHR^{bb}$, wherein the 5- to 6-membered heterocyclyl of R^{j1} is unsubstituted or substituted with one or more substituents selected from the group consisting of C_1 - C_6 alkyl, C_3 - C_8 cycloalkyl, $=O$, $-C(O)NH$ - C_1 - C_6 alkyl, and $-C(O)O$ - C_1 - C_6 alkyl, and the 5- to 6-membered heteroaryl and 6- to 12-membered aryl of R^{j1} are each independently unsubstituted or substituted with one or more substituents selected from the group consisting of C_1 - C_6 alkyl, C_3 - C_8 cycloalkyl, and $-C(O)O$ - C_1 - C_6 alkyl;

R^{bb} is unsubstituted or substituted C_1 - C_6 alkyl, unsubstituted or substituted C_3 - C_8 cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted heterocycloalkyl, or unsubstituted or substituted heteroaryl;

each R^{k1} is independently C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_3 - C_8 cycloalkyl, or 6- to 12-membered aryl, wherein the C_1 - C_6 alkyl of R^{k1} is unsubstituted or substituted with a 5- to 6-membered heterocyclyl or a 5- to 6-membered heteroaryl;

R^{3A} is H, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, or halogen, wherein the C_1 - C_6 alkyl and C_1 - C_6 alkoxy of R^{3A} are each independently unsubstituted or substituted with one or more halogen;

 indicates that the ring is saturated, partially unsaturated, or fully unsaturated;

Y_3 is $CH(X_{1A}-R^{6a1})$, $C(X_{1A}-R^{6a1})$, N, $N(X_{1A}-R^{6a1})$, S, or O;



Y_4 is $CH(X_{2A}-R^{6b1})$, $C(X_{2A}-R^{6b1})$, N, $N(X_{2A}-R^{6b1})$, S, or O;

Y_5 is $CH(X_{3A}-R^{6c1})$, $C(X_{3A}-R^{6c1})$, N, $N(X_{3A}-R^{6c1})$, S, or O;

Y_6 is $CH(X_{4A}-R^{6d1})$, $C(X_{4A}-R^{6d1})$, N, $N(X_{4A}-R^{6d1})$, S, or O;

Y_7 is N, C, or CH; and

Y_8 is N, NH, C, or CH;

X_{1A} , X_{2A} , X_{3A} , and X_{4A} are each independently absent, , or ;

m_1 is 1-6;

R^{6a1} , R^{6b1} , R^{6c1} , and R^{6d1} are each independently hydrogen, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, halo, -OH, $-NR^{p1}R^{q1}$, C_6 - C_{12} aryl, 3- to 10-membered heterocyclyl, 5- to 10-membered heteroaryl, $-C_1$ - C_6 alkyl-5- to 6-membered heterocyclyl, $-OC(O)$ -5- to 6-membered heterocyclyl, $-C(O)R^{h1}$, $-S(O)_2NR^{w1a}R^{w2a}$, $-S(O)_2R^{y1}$, $-NR^{z1a}S(O)_2R^{z2a}$, or $-N(CH_3)CH_2C(CH_3)_3$, wherein the C_1 - C_6 alkyl and C_1 - C_6 alkoxy of R^{6a1} , R^{6b1} , R^{6c1} , and R^{6d1} are each independently unsubstituted or substituted with one or more groups selected from the group consisting of C_3 - C_8 cycloalkyl and halogen; the C_6 - C_{12} aryl and 5- to 10-membered heteroaryl of R^{6a1} , R^{6b1} , R^{6c1} , and R^{6d1} are each independently unsubstituted or substituted with one or more groups selected from the group consisting of C_1 - C_6 alkyl, C_1 - C_6 alkoxy, -OH, and C_1 - C_6 alkyl-OH; and the 3- to 10-membered heterocyclyl, $-C_1$ - C_6 alkyl-5- to 6-membered heterocyclyl, and $-OC(O)$ -5- to 6-membered heterocyclyl of R^{6a1} , R^{6b1} , R^{6c1} , and R^{6d1} are each independently unsubstituted or substituted with one or more groups selected from the group consisting of C_1 - C_6 alkyl, C_1 - C_6 alkoxy, -OH, C_1 - C_6 alkyl-OH, $=O$, $=S$, , halo, C_3 - C_8 cycloalkyl, $-C(O)NH$ - C_3 - C_8 cycloalkyl, C_6 - C_{12} aryl, and 5- to 6-membered heterocyclyl;

each R^{h1} is independently selected from the group consisting of H, C_1 - C_6 alkyl, C_1 -

C_6 alkoxy, C_3 - C_8 cycloalkyl, and $-NR^{r1}R^{s1}$;

each R^{p1} is independently H or C_1 - C_6 alkyl;

each R^{q1} is independently C_2 - C_3 alkyl, $-C(O)R^{t1}$, $-C(O)OR^{u1}$, or $-C(O)NR^{v1}$;

each R^{r1} , R^{s1} , R^{w1a} , and R^{z1a} is independently selected from H and C_1 - C_6 alkyl; and


each R^{t1} , R^{u1} , R^{v1} , R^{w2a} , R^{y1} , and R^{z2a} is independently selected from H, C_1 - C_6 alkyl, unsubstituted or substituted C_3 - C_8 cycloalkyl, and unsubstituted or substituted heterocyclyl;

or

Y_5 is $CH(X_{3A}-R^{6c1})$ or $C(X_{3A}-R^{6c1})$, Y_6 is $CH(X_{4A}-R^{6d1})$ or $C(X_{4A}-R^{6d1})$, and R^{6c1} and R^{6d1} are taken together with the carbon atoms to which they are attached to form a 6-membered aryl, a 6-membered heterocyclyl, or a 6-membered heteroaryl ring; wherein the 6-membered aryl, 6-membered heterocyclyl, and 6-membered heteroaryl rings are each independently unsubstituted or substituted with one or more groups selected from the group consisting of C_1 - C_6 alkyl and $-C(O)O-C_1$ - C_6 alkyl;


wherein no more than one of R^{6a1} , R^{6b1} , R^{6c1} , and R^{6d1} is C_1 - C_6 alkoxy or $-OH$; and

(1) when L is $-C\equiv C-$, Y_1 and Y_2 are each CH, one of R^{1A} and R^{2A} is $-C(O)H$, $-CH_2OH$, -




$C(O)CH_3$ or $-NHC(O)CH_3$, and R^{3A} is H, is other than cyclohexyl, phenyl, pyridyl, or naphthyl, and R^{6c1} is hydrogen, C_2 - C_3 alkyl, C_2 - C_5 alkoxy, Br, Cl, I, $-NR^{p1}R^{q1}$, C_6 - C_{12} aryl, 3- to 10-membered heterocyclyl, 5- to 10-membered heteroaryl, $-C_1$ - C_6 alkyl-5- to 6-membered heterocyclyl, $-OC(O)$ -5- to 6-membered heterocyclyl, $-C(O)R^{h1}$, $-S(O)_2NR^{w1a}R^{w2a}$, $-S(O)_2R^{y1}$, or $-NR^{z1a}S(O)_2R^{z2a}$, and each R^{h1} is independently selected from the group consisting of C_1 - C_6 alkyl, C_1 - C_6 alkoxy, C_3 - C_8 cycloalkyl, and $-NR^{r1}R^{s1}$;


(2) when L is $-C\equiv C-$, Y_1 and Y_2 are each CH, one of R^{1A} and R^{2A} is $-C(O)H$, and R^{3A} is -




CH_3 , t-Bu, or C_2 - C_3 alkoxy, is other than phenyl and pyridyl, R^{b1} and R^{d1} are other

than , and R^{6c1} is other than $-OH$;


(3) when L is $-C\equiv C-$, Y_1 and Y_2 are each CH, one of R^{1A} and R^{2A} is piperidinyl, pyrrolidinyl, pyrrolidinone, piperazinyl, morpholinyl, or thiadiazolidinone 1,1-dioxide, and R^{3A}

is H,  is other than naphthyl, and R^{6c1} is other than fluoro;



(4) when L is $^*-NHS(O)_2-$ or $^*-S(O)_2NH-$, Y_1 and Y_2 are each CH, one of R^{1A} and R^{2A} is

$-C(O)H$, $-CH=NR^{j1}$, or , and R^{3A} is H or Br,  is other than phenyl, and R^{6a1} , R^{6b1} , R^{6c1} , and R^{6d1} are each independently hydrogen, C_2 - C_6 alkyl, C_1 - C_6 alkoxy, $-OH$, $-NR^{p1}R^{q1}$, C_6 - C_{12} aryl, 3- to 10-membered heterocyclyl, 5- to 10-membered heteroaryl, $-C_1$ - C_6 alkyl-5- to 6-membered heterocyclyl, $-OC(O)$ -5- to 6-membered heterocyclyl, $-C(O)R^{h1}$, $-S(O)_2NR^{w1a}R^{w2a}$, $-S(O)_2R^{y1}$, or $-NR^{z1a}S(O)_2R^{z2a}$;

(5) when L is $^*-C(O)NH-$ or $^*-NHC(O)-$, Y_1 and Y_2 are each CH, one of R^{1A} and R^{2A} is -

$C(O)H$, and R^{3A} is H or Cl,  is other than phenyl, and R^{6a1} is other than $-CF_3$; and

(6) when L is $-NHC(O)NH-$, Y_1 and Y_2 are each CH, one of R^{1A} and R^{2A} is $-C(O)H$ or

, and R^{3A} is H or Cl,  is other than cyclohexyl, and R^{6c1} is other than chloro.

48. The compound of claim 47, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^{6a1} , R^{6b1} , R^{6c1} , and R^{6d1} are each independently hydrogen, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, halo, $-OH$, $-NR^{p1}R^{q1}$, C_6 - C_{12} aryl, 3- to 10-membered heterocyclyl, 5- to 10-membered heteroaryl, $-C_1$ - C_6 alkyl-5- to 6-membered heterocyclyl, $-OC(O)$ -5- to 6-membered heterocyclyl, $-C(O)R^{h1}$, $-S(O)_2NR^{w1a}R^{w2a}$, $-S(O)_2R^{y1}$, or $-NR^{z1a}S(O)_2R^{z2a}$, wherein the C_1 - C_6 alkyl and C_1 - C_6 alkoxy of R^{6a1} , R^{6b1} , R^{6c1} , and R^{6d1} are each independently unsubstituted or

substituted with one or more groups selected from the group consisting of C₃-C₈ cycloalkyl and halogen; the C₆-C₁₂ aryl and 5- to 10-membered heteroaryl of R^{6a1}, R^{6b1}, R^{6c1}, and R^{6d1} are each independently unsubstituted or substituted with one or more groups selected from the group consisting of C₁-C₆alkyl, C₁-C₆alkoxy, -OH, and C₁-C₆alkyl-OH; and the 3- to 10-membered heterocyclyl, -C₁-C₆alkyl-5- to 6-membered heterocyclyl, and -OC(O)-5- to 6-membered heterocyclyl of R^{6a1}, R^{6b1}, R^{6c1}, and R^{6d1} are each independently unsubstituted or substituted with one or more groups selected from the group consisting of C₁-C₆alkyl, C₁-C₆alkoxy, -OH, C₁-C₆alkyl-OH, =O, and =S.

49. The compound of claim 47 or claim 48, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein Y₁ and Y₂ are each CH.

50. The compound of claim 47 or claim 48, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein Y₁ is CF, CCl, or CBr.

51. The compound of any one of claims 47-48 and 50, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein Y₂ is CF, CCl, or CBr.

52. The compound of claim 47 or claim 48, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein Y₁ is CH and Y₂ is N.

53. The compound of claim 47 or claim 48, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein Y₁ is N and Y₂ is CH.


54. The compound of any one of claims 47-53, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^{1A} is -OH and R^{2A} is selected from the group consisting of -C(O)R^{a1}, -CH=NR^{j1}, -S(O)R^{b1}, -S(O)₂R^{c1}, -NHC(O)R^{d1}, -NHS(O)₂R^{e1}, -C₁-C₆alkyl-R^{f1}, -C₂-C₆alkenyl-R^{g1}, C₃-C₈ cycloalkyl, C₃-C₈ cycloalkenyl, and 5- or 6-membered heterocycloalkyl.

55. The compound of any one of claims 47-53, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^{1A} is $-OH$ and R^{2A} is $-C(O)R^{a1}$.

56. The compound of claim 55, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^{1A} is $-OH$ and R^{2A} is $-C(O)H$.

57. The compound of any one of claims 47-53, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^{1A} is $-OH$ and R^{2A} is $-CHNR^{j1}$.

58. The compound of claim 57, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^{1A} is $-OH$ and R^{2A} is selected from the group consisting of



59. The compound of any one of claims 47-53, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^{1A} is $-OH$ and R^{2A} is




60. The compound of any one of claims 47-53, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^{2A} is $-OH$ and R^{1A} is selected from the group consisting of $-C(O)R^{a1}$, $-CH=NR^{j1}$, $-S(O)R^{b1}$, $-S(O)_2R^{c1}$, $-NHC(O)R^{d1}$, $-NHS(O)_2R^{e1}$, $-C_1$ - C_6 alkyl- R^{f1} , $-C_2$ - C_6 alkenyl- R^{g1} , C_3 - C_8 cycloalkyl, C_3 - C_8 cycloalkenyl, and 5- or 6-membered heterocycloalkyl.


61. The compound of any one of claims 47-53, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^{2A} is $-OH$ and R^{1A} is $-C(O)R^{a1}$.

62. The compound of claim 61, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^{2A} is $-OH$ and R^{1A} is $-C(O)H$.

63. The compound of any one of claims 47-53, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^{2A} is $-OH$ and R^{1A} is $-CHNR^{j1}$.

64. The compound of claim 63, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^{2A} is $-OH$ and R^{1A} is selected from the group consisting of





65. The compound of any one of claims 47-53, or a tautomer thereof, or a pharmaceutically

acceptable salt of any of the foregoing, wherein R^{2A} is $-OH$ and R^{1A} is .

66. The compound of any one of claims 47-65, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein L is $-C\equiv C-$.

67. The compound of any one of claims 47-53, 56-59, and 62-65, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein L is $^*-NHC(O)-$ or $^*-C(O)NH-$.

68. The compound of any one of claims 47-53, 56-59, and 62-65, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein L is $-NHC(O)NH-$ or $^*-NHC(O)O-$.

69. The compound of any one of claims 47-53, 56-59, and 62-65, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein L is $^*-NHS(O)_2-$ or $^*-S(O)_2NH-$.

70. The compound of any one of claims 47-53, 56-59, and 62-65, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein L is $^*-S(O)NHNH-$, $^*-NHNHS(O)-$, $^*-NHNHC(O)-$, or $^*-C(O)NHNH-$.



71. The compound of any one of claims 47-70, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^{3A} is selected from the group consisting of C_1 - C_6 alkyl, C_1 - C_6 alkoxy, and halogen, wherein the C_1 - C_6 alkyl and C_1 - C_6 alkoxy of R^{3A} are each independently unsubstituted or substituted with one or more halogen.

72. The compound of any one of claims 47-71, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^{3A} is $-OCH_3$ or F.



73. The compound of any one of claims 47-71, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^{3A} is F.

74. The compound of any one of claims 47-70, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^{3A} is H.



75. The compound of any one of claims 47-74, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein Y_3 is $CH(X_{1A}-R^{6a1})$ or $C(X_{1A}-R^{6a1})$; X_{1A} is

absent, , or ; m_1 is 1-6; R^{6a1} is hydrogen, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, halo, C_6 - C_{12} aryl, 3- to 10-membered heterocyclyl, or 5- to 10-membered heteroaryl.

76. The compound of any one of claims 47-74, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein Y_3 is N or $N(X_{1A}-R^{6a1})$; X_{1A} is absent,


, or ; m_1 is 1-6; and R^{6a1} is hydrogen, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, halo, C_6 - C_{12} aryl, 3- to 10-membered heterocyclyl, or 5- to 10-membered heteroaryl.

77. The compound of any one of claims 47-76, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein Y_4 is $CH(X_{2A}-R^{6b1})$ or $C(X_{2A}-R^{6b1})$; X_{2A} is


absent, , or ; m_1 is 1-6; and R^{6b1} is hydrogen, C_1 - C_6 alkyl, C_1 -

C₆haloalkyl, halo, C₆-C₁₂ aryl, 3- to 10-membered heterocyclyl, or 5- to 10-membered heteroaryl.


78. The compound of any one of claims 47-76, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein Y₄ is N or N(X_{2A}-R^{6b1}); X_{2A} is absent,



79. The compound of any one of claims 47-78, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein Y₅ is CH(X_{3A}-R^{6c1}) or C(X_{3A}-R^{6c1}); X_{3A} is




80. The compound of any one of claims 47-78, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein Y₅ is N or N(X_{3A}-R^{6c1}); X_{3A} is absent,




81. The compound of any one of claims 47-80, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein one of Y₃, Y₄, and Y₅ is S or O.

82. The compound of any one of claims 47-81, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein Y₆ is CH(X_{4A}-R^{6d1}) or C(X_{4A}-R^{6d1}); X_{4A} is



83. The compound of any one of claims 47-82, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein Y_6 is N or $N(X_{4A}-R^{6d1})$; X_{4A} is absent,



; m_1 is 1-6; and R^{6d1} is hydrogen, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, halo, C_6 - C_{12} aryl, 3- to 10-membered heterocyclyl, or 5- to 10-membered heteroaryl.

84. The compound of any one of claims 47-78 and 81, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein Y_5 is $CH(X_{3A}-R^{6c1})$ or $C(X_{3A}-R^{6c1})$, Y_6 is $CH(X_{4A}-R^{6d1})$ or $C(X_{4A}-R^{6d1})$, and R^{6c1} and R^{6d1} come together with the carbon atoms to which they are attached to form a 6-membered aryl, a 6-membered heterocyclyl, or a 6-membered heteroaryl ring; wherein the 6-membered aryl, 6-membered heterocyclyl, and 6-membered heteroaryl rings are each independently unsubstituted or substituted with one or more groups selected from the group consisting of C_1 - C_6 alkyl and $-C(O)O-C_1$ - C_6 alkyl.

85. The compound of any one of claims 47-84, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein Y_7 is N.

86. The compound of any one of claims 47-84, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein Y_7 is C or CH.

87. The compound of any one of claims 47-86, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein one or more of R^{6a1} , R^{6b1} , R^{6c1} , and R^{6d1} is selected from the group consisting of C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, halo, C_6 - C_{12} aryl, 3- to 10-membered heterocyclyl, and 5- to 10-membered heteroaryl.

88. The compound of any one of claims 47-87, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein one of R^{6a1} , R^{6b1} , R^{6c1} , and R^{6d1} is selected from the group consisting of C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, halo, C_6 - C_{12} aryl, 3- to 10-membered heterocyclyl, and 5- to 10-membered heteroaryl.

89. The compound of any one of claims 47-86, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein one of R^{6a1} , R^{6b1} , R^{6c1} , and R^{6d1} is selected from the group consisting of methyl, ethyl, F, Cl, $-CF_3$, pyrrolidinyl, piperidinyl, morpholinyl, pyrazolyl, and triazolyl.
90. The compound of any one of claims 47-86, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^{6a1} , R^{6b1} , R^{6c1} , and R^{6d1} are each H.
91. A compound of Table 1B, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.
92. A pharmaceutical composition comprising at least one compound according to any one of claims 1-91, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, optionally further comprising a pharmaceutically acceptable excipient.
93. A method of treating a disease or condition associated with TLR2 heterodimerization, comprising administering to a subject in need of such treatment an effective amount of at least one compound according to any one of claims 1-91, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a pharmaceutical composition of claim 92.
94. The method of claim 93, wherein the disease or condition is selected from the group consisting of: Alzheimer's disease, Parkinson's disease, fronto-temporal dementia, dementia with Lewy bodies (Lewy body disease), Parkinson's disease with dementia, multiple system atrophy, amyotrophic lateral sclerosis, Huntington's disease, Progressive Supranuclear Palsy (PSP), Niemann-Pick disease type C, inflammatory diseases, asthma, chronic obstructive pulmonary disease (COPD), chronic peptic ulcers, irritable bowel disease, tuberculosis, rheumatoid arthritis, osteoarthritis, chronic sinusitis, hepatitis, hepatitis B, hepatitis C, gout, lupus, pleurisy, eczema, gastritis, psoriasis, psoriatic arthritis, vasculitis, laryngitis, allergic reactions, multiple sclerosis, Crohn's disease, traumatic brain injury, CIDP (chronic inflammatory demyelinating polyneuropathy), stroke, ischemic heart disease, atopic dermatitis, acne vulgaris, rosacea, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, corneal wounds, corneal disorders, corneal HSV, Stargardt disease (Juvenile macular degeneration),

age-related macular degeneration, sepsis, diabetic wounds, herpes simplex virus, and anti-fungal, anti-bacterial, antiviral and antitumor diseases or conditions.

95. A compound of any one of claims 1-91, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a pharmaceutical composition of claim 92, for use in the treatment of a disease or condition associated with TLR2 heterodimerization.

96. The compound of claim 95, wherein the disease or condition is selected from the group consisting of: Alzheimer's disease, Parkinson's disease, fronto-temporal dementia, dementia with Lewy bodies (Lewy body disease), Parkinson's disease with dementia, multiple system atrophy, amyotrophic lateral sclerosis, Huntington's disease, Progressive Supranuclear Palsy (PSP), Niemann-Pick disease type C, inflammatory diseases, asthma, chronic obstructive pulmonary disease (COPD), chronic peptic ulcers, irritable bowel disease, tuberculosis, rheumatoid arthritis, osteoarthritis, chronic sinusitis, hepatitis, hepatitis B, hepatitis C, gout, lupus, pleurisy, eczema, gastritis, psoriasis, psoriatic arthritis, vasculitis, laryngitis, allergic reactions, multiple sclerosis, Crohn's disease, traumatic brain injury, CIDP (chronic inflammatory demyelinating polyneuropathy), stroke, ischemic heart disease, atopic dermatitis, acne vulgaris, rosacea, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, corneal wounds, corneal disorders, corneal HSV, Stargardt disease (Juvenile macular degeneration), age-related macular degeneration, sepsis, diabetic wounds, herpes simplex virus, and anti-fungal, anti-bacterial, antiviral and antitumor diseases or conditions.

97. Use of at least one compound of any one of claims 1-91, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a pharmaceutical composition of claim 92, in the manufacture of a medicament for the treatment of a disease or condition associated with TLR2 heterodimerization.

98. The use of claim 97, wherein the disease or condition is selected from the group consisting of: Alzheimer's disease, Parkinson's disease, fronto-temporal dementia, dementia with Lewy bodies (Lewy body disease), Parkinson's disease with dementia, multiple system atrophy, amyotrophic lateral sclerosis, Huntington's disease, Progressive Supranuclear Palsy

(PSP), Niemann-Pick disease type C, inflammatory diseases, asthma, chronic obstructive pulmonary disease (COPD), chronic peptic ulcers, irritable bowel disease, tuberculosis, rheumatoid arthritis, osteoarthritis, chronic sinusitis, hepatitis, hepatitis B, hepatitis C, gout, lupus, pleurisy, eczema, gastritis, psoriasis, psoriatic arthritis, vasculitis, laryngitis, allergic reactions, multiple sclerosis, Crohn's disease, traumatic brain injury, CIDP (chronic inflammatory demyelinating polyneuropathy), stroke, ischemic heart disease, atopic dermatitis, acne vulgaris, rosacea, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, corneal wounds, corneal disorders, corneal HSV, Stargardt disease (Juvenile macular degeneration), age-related macular degeneration, sepsis, diabetic wounds, herpes simplex virus, and anti-fungal, anti-bacterial, antiviral and antitumor diseases or conditions.

99. A method of interfering with the heterodimerization of TLR2 in a cell, or modulating, preventing, slowing, reversing, or inhibiting TLR2 heterodimerization in a cell, comprising contacting the cell with an effective amount of at least one compound according to any one of claims 1-91, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and/or with at least one pharmaceutical composition according to claim 92, wherein the contacting is *in vitro*, *ex vivo*, or *in vivo*.

100. A method of inhibiting TLR2 activation in a cell, comprising contacting the cell with an effective amount of at least one compound according to any one of claims 1-91, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and/or with at least one pharmaceutical composition according to claim 92, wherein the contacting is *in vitro*, *ex vivo*, or *in vivo*.

101. A method of treating a disease or condition associated with inhibition of TLR9, comprising administering to a subject in need of such treatment an effective amount of at least one compound according to any one of claims 1-91, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a pharmaceutical composition of claim 92.

102. The method of claim 93, wherein the disease or condition is central nervous system (CNS) or peripheral disorder.

103. The method of claim 101 or claim 102, wherein the disease or condition is Parkinson's disease, Amyotrophic lateral sclerosis, Guillain-Barre syndrome, spinal cord injury, multiple sclerosis, multiple forms of tissue injury, chronic pain, or psoriasis.

104. A compound of any one of claims 1-91, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a pharmaceutical composition of claim 92, for use in the treatment of a disease or condition associated with inhibition of TLR9.

105. The compound of claim 104, wherein the disease or condition is central nervous system (CNS) or peripheral disorder.

106. The compound of claim 104 or claim 105, wherein the disease or condition is Parkinson's disease, Amyotrophic lateral sclerosis, Guillain-Barre syndrome, spinal cord injury, multiple sclerosis, multiple forms of tissue injury, chronic pain, or psoriasis.

107. Use of at least one compound of any one of claims 1-91, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a pharmaceutical composition of claim 92, in the manufacture of a medicament for the treatment of a disease or condition associated with inhibition of TLR9.

108. The use of claim 107, wherein the disease or condition is central nervous system (CNS) or peripheral disorder.

109. The use of claim 107 or claim 108, wherein the disease or condition is Parkinson's disease, Amyotrophic lateral sclerosis, Guillain-Barre syndrome, spinal cord injury, multiple sclerosis, multiple forms of tissue injury, chronic pain, or psoriasis.

110. A method of inhibiting TLR9 in a cell, comprising contacting the cell with an effective amount of at least one compound according to any one of claims 1-91, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and/or with at least one pharmaceutical composition according to claim 92, wherein the contacting is *in vitro*, *ex vivo*, or *in vivo*.